Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia

Optimal conditioning therapy for hematopoietic cell transplantation (HCT) in acute myelogenous leukemia (AML) remains undefined. We retrospectively compared outcomes of a consecutive series of 51 AML patients treated with oral busulfan (1 mg/kg every 6 hours for 4 days) and cyclophosphamide (60 mg/k...

Descripción completa

Detalles Bibliográficos
Autores principales: Pidala, Joseph, Kim, Jongphil, Anasetti, Claudio, Kharfan-Dabaja, Mohamed A, Nishihori, Taiga, Field, Teresa, Perkins, Janelle, Perez, Lia, Fernandez, Hugo F
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958877/
https://www.ncbi.nlm.nih.gov/pubmed/20925957
http://dx.doi.org/10.1186/1756-8722-3-36

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958877/
https://www.ncbi.nlm.nih.gov/pubmed/20925957
http://dx.doi.org/10.1186/1756-8722-3-36

Ejemplares similares